Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

H. pylori eradication therapy treatment for localized H. pylori-negative gastric MALT lymphoma

Eradication of Helicobacter pylori is a well-accepted initial therapy in cases of localized (stage ⅠE) low-grade gastric mucosa-associated lymphoid tissue lymphoma associated with H. pylori infection. However, there are no treatment guidelines for the management of H. pylori-negative low-grade gastric MALT lymphoma.

7 May 2010

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Colorectal cancer is one of the major causes of cancer death in the developed countries. Accumulated evidences indicate that lipid metabolism, especially the one in the arachidonic acid -pathway, appears to play a critical role in the development of CRC.

7 May 2010

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Gastric cancer is the most common malignant gastrointestinal cancer and accounts for 25% of cancer deaths. Nuclear matrix, a filamentous protein framework for eukaryotic cellular chromatin, closely relates to DNA duplication and transcription. Research on nuclear matrix proteins will provide insight into how tumors developed.

7 May 2010

Hepcidin is found in various biological fluids, says new research

Recent studies have highlighted the importance of hepcidin in iron metabolism, particularly anaemia of chronic disease and iron overload. There have also been reports of its expression in various proinflammatory disorders and various organs, linking it to innate immunity and iron metabolism.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

ArQule, Inc. today announced its financial results for the first quarter of 2010.

6 May 2010

Use of combined PET/CT can confirm suspected colorectal cancer recurrence at early stage: Study

The use of combined positron emission tomography and computed tomography can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment planning and improved targeted patient care, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Colorectal pre-cancer can be detected through stool DNA testing: Mayo Clinic study

Research teams led by Mayo Clinic have demonstrated for the first time that two types of colorectal pre-cancers can be detected through noninvasive stool DNA testing. The two studies being presented demonstrate that stool DNA testing may be useful for detection of premalignant dysplasia in patients with inflammatory bowel disease and of an important type of colorectal pre-cancer called serrated polyps.

5 May 2010

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Rates of colorectal cancer screening vary by race and ethnicity as well as method, according to data being presented at Digestive Disease Week- 2010. Scientists examine data on minority and older populations as well as utilization rates of virtual and optical colonoscopies to better understand adherence to recommended screening guidelines.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Pro-Pharmaceuticals closes $310,000 private placement tranche

Pro-Pharmaceuticals, Inc., today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million.

4 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

Saving Billions Of Dollars--And Physicians' Time--By Streamlining Billing Practices - "The U.S. system of billing third parties for health care services is complex, expensive, and inefficient," write the authors, who analyzed Massachusetts General Physicians Organization staffing and cost data in fiscal year 2006.

3 May 2010

Study indicates older women with diabetes have increase risk for colon cancer

A research team led by Mayo Clinic physicians has found that older women with diabetes face a more than doubled risk for some types of colorectal cancer.

3 May 2010

Research shows microRNA can silence genes that protect genome from cancer-causing mutations

New research shows for the first time that molecules called microRNA can silence genes that protect the genome from cancer-causing mutations.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Study identifies extracapsular LNI as a negative prognostic factor for esophageal cancer

There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional esophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected esophageal cancer.

30 Apr 2010

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Acellular dermal matrix (ADM) is a dermal biomaterial in which all of the cellular elements have been removed. The biologic properties of ADM, including its ability to support tissue regeneration repopulation with fibroblasts, revascularization, new collagen deposition and eventual absorption and replacement with native tissue permit its use in tissue reconstruction.

29 Apr 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

H. pylori eradication therapy treatment for localized H. pylori-negative gastric MALT lymphoma

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Hepcidin is found in various biological fluids, says new research

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Curis reports net income of $4.8M for first-quarter 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

Use of combined PET/CT can confirm suspected colorectal cancer recurrence at early stage: Study

Colorectal pre-cancer can be detected through stool DNA testing: Mayo Clinic study

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Pro-Pharmaceuticals closes $310,000 private placement tranche

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

Study indicates older women with diabetes have increase risk for colon cancer

Research shows microRNA can silence genes that protect genome from cancer-causing mutations

REGN reports net loss of $30.5M for first-quarter 2010

Study identifies extracapsular LNI as a negative prognostic factor for esophageal cancer

Study investigates efficacy of acellular dermal matrix for intestinal elongation

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in